# OnCo record locally-advanced-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/locally-advanced-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "locally-advanced-pdac" ;
  schema:name "Locally advanced unresectable pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "Locally advanced pancreatic cancer"@en, "LAPC"@en, "Unresectable non-metastatic pancreatic cancer"@en, "Stage III pancreatic adenocarcinoma"@en ;
  schema:description "Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."@en ;
  schema:url <https://onco.cc/cancers/locally-advanced-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Pancreatic_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/msi-high-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/irreversible-electroporation/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/technologies/pet-ct/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/fap/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zoldonrasib/> ;
  onco:companies <https://onco.cc/companies/novocure/>, <https://onco.cc/companies/revolution-medicines/> ;
  onco:pathways <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/caf-activation-desmoplasia/>, <https://onco.cc/pathways/cachexia-biology/> ;
  onco:terms <https://onco.cc/terms/locally-advanced/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/sbrt-term/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/terms/biliary-stent/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/desmoplasia/> ;
  onco:trials <https://onco.cc/trials/panova-3/>, <https://onco.cc/trials/nct05653453/>, <https://onco.cc/trials/nct05466799/>, <https://onco.cc/trials/nct06850623/>, <https://onco.cc/trials/nct07157033/>, <https://onco.cc/trials/nct04390399/> ;
  onco:people <https://onco.cc/people/theodore-hong/>, <https://onco.cc/people/albert-koong/>, <https://onco.cc/people/theodore-lawrence/>, <https://onco.cc/people/eileen-oreilly/>, <https://onco.cc/people/tobias-janowitz/>, <https://onco.cc/people/hedy-kindler/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/>, <https://onco.cc/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/> ;
  onco:pipeline <https://onco.cc/trials/nct05653453/>, <https://onco.cc/trials/nct05466799/>, <https://onco.cc/trials/nct06850623/>, <https://onco.cc/trials/nct07157033/>, <https://onco.cc/trials/nct04390399/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/technologies/irreversible-electroporation/>, <https://onco.cc/ideas/idea-reg-losartan-pancreatic-stroma/>, <https://onco.cc/ideas/idea-fund-adaptive-radiotherapy-evidence/> ;
  onco:standardOfCare <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/cachexia/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/trials/panova-3/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/mr-linac/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/technologies/irreversible-electroporation/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/trials/rasolute-302/> .